Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas
Debono et al • 2014 • J Clin Endocrinol Metab.
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 151 entries already.
Entries by jeremiah@devisedesigns.com
The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice.
Meyer et al. • 2014 • J Steroid Biochem Mol Biol. 2014 Sep;143:40-8.
Age- and sex-dependent effects of early life stress on hippocampal neurogenesis.
Loi et al. • 2014 • Front Endocrinol (Lausanne). 2014;5:13.
A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone.
Fleseriu et al. • 2013 • Endocr Pract. 2013;19(2):313-26.
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.
Baglietto-Vargas et al. • 2013 • Biol Psychiatry. 2013;74(5):357-66.
A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation.
Hu et al. • 2012 • PLoS One. 2012;7(9):e46224.
Acute effects of neonatal dexamethasone treatment on proliferation and astrocyte immunoreactivity in hippocampus and corpus callosum: towards a rescue strategy.
Claessens et al. • 2012 • Brain Res. 2012;1482:1-12.
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome.
Fleseriu et al. • 2012 • J Clin Endocrinol Metab. 2012;97(6):2039-49.
Slowing the progression of cognitive decline in Alzheimer’s disease using mifepristone.
Belanoff et al. • 2002 • J Mol Neurosci. 2002;19(1-2):201-6.